Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection

Journal of Clinical Virology

Volumn 53, Issue 2, 2012, Pages 130-134

  Karatayli, Ersin ^a   Karatayli, Senem C ^a   Cinar, Kubilay ^a   Gokahmetoglu, Selma ^b   Güven, Kadri ^b   Idilman, Ramazan ^a   Yurdaydin, Cihan ^a   Bozdayi, A Mithat ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Drug resistance; Entecavir; Hepatitis b virus

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; INTERFERON; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CASE REPORT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENOME; VIRUS ISOLATION; VIRUS REPLICATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE, VIRAL; FATAL OUTCOME; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHOSPHONIC ACIDS; VIRUS REPLICATION;

EID: 84855545321     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.10.011     Document Type: Article

References (22)

1. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
2. Melegari M., Scaglioni P.P., Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628-633.
3. Jardi R., Buti M., Rodriguez-Frias F., Cotrina M., Costa X., Pascual C., et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999, 83:181-187.
4. Bozdayi A.M., Uzunalimoĝlu O., Türkyilmaz A.R., Aslan N., Sezgin O., Sahin T., et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003, 10:256-265.
5. Stuyver L., Van Geyt C., De Gendt S., Van Reybroeck G., Zoulim F., Leroux-Roels G., et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707.
6. Delaney W.E., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77:11833-11841.
7. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
8. Lacombe K., Ollivet A., Gozlan J., Durantel S., Tran N., Girard P.M., et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006, 14(20):2229-2231.
9. Karatayli E., Karayalçin S., Karaaslan H., Kayhan H., Türkyilmaz A.R., Sahin F., et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12:761-768.
10. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 27(354):1807-1812.
11. Bartholomeusz A., Locarnini S.A. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006, 26:162-170.
12. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
13. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006, 44:1656-1665.
14. Snow-Lampart A., Chappell B., Curtis M., Zhu Y., Myrick F., Schawalder J., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
15. Gunther S., Li B.C., Miska S., Kruger D.H., Meisel H., Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995, 69:5437-5444.
16. Yang H., Westland C., Xiong S., Delaney W.E. In vitro antiviral susceptibility of full-length clinical hepatitis b virus isolates cloned with a novel expression vector. Antiviral Res 2004, 61:27-36.
17. Bozkaya H., Yurdaydin C., Idilman R., Tüzün A., Cinar K., Erkan O., et al. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther 2005, 10:319-325.
18. Yurdaydin C. Entecavir: a step forward in combating hepatitis B disease. Expert Opin Pharmacother 2008, 9:3095-3109.
19. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrell D.L.J., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998, 27:1670-1677.
20. Seta T., Yokosuka O., Imazeki F., Tagawa M., Saisho H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000, 60:8-16.
21. Qi X., Xiong S., Yang H., Miller M., Delaney W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007, 12:355-362.
22. Peters M.G., Hann Hw H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91-101.